GLP-1 receptor agonists (RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is), which enhance GLP-1 function, may be used to compensate for the GLP-1 deficiency due to circadian rhythm dysfunction and obesity [66,72]. Here, GCG is linked to Obesity.